MedTrace Logo

Evaluating Girls Invest: A Mobile-Enabled Economic Empowerment Intervention for Girls to Reduce Risk for Partner Violence

NCT06942481 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2025-04-27

No results posted yet for this study

Summary

The research aims to refine and evaluate Girls Invest, a newly developed economic empowerment intervention, to reduce economic and social risks associated with high rates of intimate partner violence (IPV) among adolescent girls in Ibadan, Nigeria. Girls Invest, initially developed and tested in the US, has been adapted for use in Nigeria via Phase I Wellspring support. Girls Invest participants complete gender equity and financial skills training modules via a mobile "app." Upon completion, each participant receives a financial resource of supporting girls' education/vocation (e.g., sewing machine, baking oven and pans, or funds to cover educational exams).

Conditions

  • Risk Factors for Intimate Partner Violence

Interventions

BEHAVIORAL

Girls Invest

The Girls Invest intervention involved: 1) app-based trainings on topics related to financial literacy, gender equity, and health and 2) financial resources/incentives supporting girls' education/career.

BEHAVIORAL

Waitlist control

Participants receive Girls Invest after they complete the 6 month follow-up survey.

Sponsors & Collaborators

  • University of Ibadan

    collaborator OTHER

  • San Diego State University

    lead OTHER

Principal Investigators

  • Elizabeth Reed · San Diego State University

  • Olufunmilayo Fawole · University of Ibadan

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
19 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-07
Primary Completion
2023-09-15
Completion
2023-09-15

Countries

  • Nigeria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06942481 on ClinicalTrials.gov